A Roadmap to Treatment Beyond Steroids
Sara Wood, ND
Since her husband passed away six years ago and she wasn’t dating, Sheila hadn’t given much thought to her vulva until her gynecologist mentioned, during a routine exam, that her lichen sclerosus had progressed and her clitoral hood was starting to fuse. She didn’t even remember being told that she had lichen sclerosus, but apparently it was in her chart, observed and “diagnosed” years prior. Sheila was alarmed, though her clitoris had been admittedly underused over the past few years, she certainly didn’t want it sealed away! Her doctor told her that the diagnosis may not have been emphasized to her at the time it was originally observed because she wasn’t experiencing any symptoms. Bewildered and confused, Sheila returned home to process this new information and to do some research, and she found that she wasn’t alone. Online forums were filled with stories like hers, or worse. Many women who were symptomatic, experiencing severe itching or pain, who were still undertreated or told that there wasn’t much that could be done. Those that were treated were primarily given steroid creams of varying strengths that sometimes helped, but often they weren’t advised on a long-term management strategy. Reasons for this shortcoming in treatment are multifaceted but include the sensitive nature of the subject and the counseling required to fully address it. Unfortunately, many physicians don’t have the luxury of time required to discuss the emotional impact of labial fusion, let alone the time needed to discuss underlying causes and possible lifestyle changes.
It’s not a household word, but lichen sclerosus isn’t exactly rare; one study found a prevalence of 1.7% in a general gynecology practice,(1) although many women have never heard of it until they read it on a pathology report or their doctor prescribes them a steroid cream. For some, like Sheila, the symptoms are mild or even absent and the condition is discovered upon routine exam; for others, itching or pain with sex are what lead them to investigate the problem. Since tissue changes can lead to labial fusion, narrowing of the vaginal opening and even carcinoma (in approximately 3% of cases), even the mildest of cases should be treated and monitored.
Lichen sclerosus (LS) is a chronic inflammatory disease that may initially manifest as white patches on the skin. The tissue becomes fragile and itchy; and because LS is most commonly found on genital tissues, pain with sex is a frequent presenting complaint. LS occurs in women approximately 10 times more often than men and is most common during phases of life with relatively low reproductive hormones (pre-pubertal and post-menopausal).(1) Since men make up such a small percentage of LS patients, they are often overlooked in the conversation, although the same general therapies are used for both sexes with the exception of circumcision, which is often an effective treatment in uncircumcised men.(2)
A diagnosis of lichen sclerosus typically requires a biopsy of the tissue, and the steroid creams that are the standard of care are effective at slowing tissue damage. Unfortunately, many treatment plans stop there, using a combination of different strength steroids to halt the progression of the disease. An important part in truly treating any condition is trying to understand what causes it; and while the definitive etiology of lichen sclerosus isn’t known, there is increasing evidence of an autoimmune component. Restoration of hormones, repletion of important nutrients, elimination of inflammatory foods as well as mechanical or chemical irritation and employment of immune modulating agents can have a significant impact. Beyond that, there are new studies on injection treatments that are proving to be very effective for some patients.
What Is Autoimmunity?
The immune system is an invaluable component to health, as it identifies and targets infectious organisms including bacteria, viruses, and fungi as well as eradicates random mutations in our own tissues that may lead to malignancy. This is happening behind the scenes, all the time, in every tissue in the body. But occasionally something goes wrong and the immune system targets tissue that is not foreign and is otherwise perfectly healthy. Like friendly fire, the body incorrectly attacks itself for reasons that are largely unknown, although evidence is mounting that one of the initial triggers may be gut dysfunction.(4) There are approximately 80 identified autoimmune diseases, some of which are diagnosed with a specific test for an antibody to a target tissue. Others are thought to be autoimmune but do not have an identified “marker.” Lichen sclerosus generally falls into this latter category, and there is a high rate of comorbidity with LS and autoimmunity; between 20 and 30% of women with LS have also been diagnosed with another autoimmune disease,(5,6) autoimmune thyroiditis is the most common.(7) When it comes to long-term treatment of lichen sclerosus, there are many effective ways of addressing underlying immune dysfunction that are often overlooked and can have a profound effect on symptoms as well as the overall progression of the disease.
There is a clear pattern to the demographic of lichen sclerosus patients: women who have low circulating levels of reproductive hormones are more likely to be affected.(8) When discussing changing hormone levels in peri and postmenopausal women, estrogen is invariably the first name to come to mind, and a low estrogen state does exacerbate almost all vulvovaginal disorders. Additionally, we know that estrogen helps to modulate the inflammatory response and cytokine expression,(9) as well as work to counteract the tissue thinning caused by the primary treatment with topical steroids.(10) For these reasons, topical estrogen creams are often prescribed to LS patients, although the literature actually better supports the use of testosterone. It has been observed that lichen sclerosus patients have decreased serum testosterone levels,(11) and treatment with topical testosterone is nearly as effective as clobetasol (a high potency steroid) in both establishing remission, and to prevent reoccurrence.(12)
Sex hormones are only part of the picture. As stated above, there is a close connection between hypothyroidism and LS, and stress hormones have a significant impact as well. Thyroid hormone levels should be evaluated in all patients who have received a diagnosis of lichen sclerosus, or any other autoimmune disease for that matter, as thyroid hormones have a bidirectional relationship with the immune system and can serve as a modulator of immune function and inflammatory processes.(13) Repletion of thyroid hormones, if deficient, may play a key role in improving general immune function.
Stress hormones, including cortisol, also have a very direct impact on inflammation and immune processes. Chronic stress has been implicated in increasing the risk of autoimmune disease.(14) While cortisol is ordinarily a potent anti-inflammatory agent in the body, chronic overproduction of the hormone can lead to resistance in the immune system and result in an increase in inflammatory markers.(15) Furthermore, continued chronic stress can lead to a general state of hypocortisolism through a number of mechanisms, further disrupting control over immune function.(16) As with many conditions, the symptoms and treatment of lichen sclerosus itself greatly contribute to chronic stress on top of any additional stressors the patient may be experiencing. Modulating and managing stress is a very complex and difficult task for many people, although it is important to note that the perception of stress is key in its power. Recurring negative thoughts, perseveration, and feelings of helplessness are maladaptive responses that may exaggerate the stress hormones effects on immune tissues.(17) In additionally to the emotional or psychological input, physical stressors including genital piercings, sexual trauma, chronic mechanical irritation from tight clothing or ongoing chemical irritation from compounds found in soaps or detergents can lead to inflammation and tissue changes.(18) The development of inflammatory tissue changes following trauma or irritation is often referred to as the Koebner phenomenon.(19)
Diet and Nutrients
While tissue biopsy for diagnosis, laboratory testing to identify hormone deficiency, and prescriptions for steroids, thyroid medication or testosterone require a physician, there are many things that any patient with a diagnosis of lichen sclerosus can do on their own that can greatly improve symptoms. Just the act of taking control can be empowering and reduce some of the negative impact of stress hormones,(20) adding additional benefit.
There are few published studies on the influence of diet on lichen sclerosus specifically; however there is an abundance of empirical evidence that supports this approach in autoimmunity in general and we can extrapolate data from studies done on other autoimmune diseases that illustrate the anti-inflammatory benefits of certain foods(21) and the role that foods play in triggering a leaky gut and subsequent immune dysfunction.(22) When it comes to diet changes, there are several approaches that may be worthwhile for LS patients including the avoidance of individual food sensitivities that are identified through testing and the broader elimination/challenge of foods that have been implicated in compromising intestinal barrier function and stimulating inflammation. The autoimmune paleo diet (AIP) is a modified version of a pre-agricultural diet that promotes gut healing and eliminates inflammatory foods including grains (both gluten and non-gluten containing), dairy, sugar, alcohol, legumes, nuts and seeds, nightshade vegetables, eggs and processed oils.(23) While some patients need to be extremely restrictive, others may see significant benefit by eliminating just one or two of the greatest offenders. When inflammatory foods are removed, chronic immune stimulation is reduced which leads to an improvement in symptoms. The gold standard for identification of which foods may be of individual concern is an elimination period followed by provocation. The elimination period should be done for at least 30 days, although in many cases will be done for up to a year. Foods are then re-introduced in a systematic fashion, which enables the patient to identify what the biggest culprits are.
Compromised intestinal function doesn’t just lead to immune stimulation directly but can also affect absorption of essential nutrients, which in turn can further disturb immune function. Even in people without autoimmune disease, insufficient levels of vitamin D are remarkably common due to inadequate sun exposure, lack of vitamin D-rich foods and malabsorption. Low serum vitamin D levels have been linked to several autoimmune diseases(24-27) as vitamin D plays an important role in establishing and maintaining self-tolerance by stimulating T-regulatory cells. These important immune cells (as their name suggests) work to regulate the immune system, neither stimulating or suppressing it. Recommended dosing of vitamin D varies tremendously. The recommended daily allowance (RDA) is relatively low and was generally established to prevent osteomalacia, a bone density disease that results from frank vitamin D deficiency.(28) Supplemental dosages are frequently 3-10 times the RDA and many patients are prescribed large bolus weekly doses. Regardless of how it is supplemented, target serum levels should be 75 nmol/l (30 ng/ml)(29) at a minimum and potentially twice that for autoimmune patients.
Low Dose Naltrexone
Naltrexone is a medication that blocks opioid receptors. It was first developed to treat addiction, although it was subsequently discovered that when used in very small doses (approximately 1/10th of the amount using with addicts) it stimulates the immune system. This therapy is referred to as low dose naltrexone or LDN. The temporary blocking of receptors causes an upregulation in the production of endorphins and enkephalins, which act on the immune system directly.(30) Though the use of LDN hasn’t been researched with lichen sclerosus specifically, it has been shown to improve inflammatory markers and disease outcomes in autoimmune diseases including multiple sclerosis and Crohn's disease.(31-33) Doses of LDN are typically 3.0-4.5 mg and dosed before bed to coincide with the increase in natural endorphin production overnight. In addition to the boosting of immune modulating endorphins, LDN has also been shown to influence glial cell activation, which decreases inflammatory cascades in the central nervous system and has a dramatic effect on pain.(34)
Platelet Rich Plasma
Platelet rich plasma (PRP) is prepared by concentrating the growth factors found in the blood. These factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and epithelial growth factor (EGF), are involved in the phagocytosis of fibrotic tissue, reduction in inflammation, angiogenesis stimulation, and collagen synthesis. Though most frequently used (and studied) in orthopedic medicine, healing sports injuries and torn ligaments and tendons, there are broad applications for PRP in medicine as it stimulates healing and regeneration of whatever tissue it is applied to. New studies have illustrated the use of PRP to halt the progression of lichen sclerosus and restore tissue integrity.(35) In this application, the patient’s blood is collected through routine venipuncture and then processed to specifically concentrate the platelets and growth factors. There are a number of FDA-approved, closed systems that do this effectively. The PRP is then injected into the affected tissue following the application of a topical anesthetic. Preliminary clinical trials found that half of patients were completely free of symptoms a year following treatment and nearly one-third no longer had any visible evidence of tissue changes.(36)
The internet age has provided patients more access to healthcare information than ever before in history; and while this can sometimes work to fuel health anxieties or promote dangerous home remedies, it can also provide supportive social networks and allow for learning beyond what is possible in a brief physician visit. Patients who are experiencing vulvar itching, pain with sex or visible labial fusion should absolutely seek medical care for a proper diagnosis and begin treatment that will preserve the integrity of their tissue. For patients like Sheila who are asymptomatic, or stable on steroid creams but are interested in preventing their immune system from causing additional damage to their tissues, diet changes, stress management techniques, and vitamin supplements are something they can do to augment their treatment. For hormone replacement, an LDN prescription, or PRP therapy, an informed physician will be needed; and there are an increasing number of doctors around the country who are integrating these services.
Dr. Sara Wood is in private practice in Portland, Oregon, where she focuses on immune dysfunction and endocrine imbalances including thyroid, adrenal, and sex hormones. She has lectured on bioidentical hormone replacement therapies at medical conferences, including the American Academy of Anti-Aging Medicine and the Integrative Healthcare Symposium, and authored a book in 2009 on declining testosterone levels in men titled His Change of Life: Male Menopause and Healthy Aging with Testosterone.
Outside of the clinic, Dr. Wood can be found keeping up with her two little boys, cuddling with her dog and always searching for a spot in the sun.
1. Goldstein AT, et al. Prevalence of vulvar lichen sclerosus in a general gynecology practice. J Reprod Med 2005; 50: 477.
2. Nair PA. Vulvar Lichen Sclerosus et Atrophicus. Journal of Mid-Life Health. 2017; 8(2): 55-62.
3. Kulkarni S, et al. Lichen sclerosus of the male genitalia and urethra: surgical options and results in a multicenter international experience with 215 patients. Eur Urol. 2009; 55: 945–954.
4. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases Annals of the New York Academy of Sciences 2012: 1258; 25-33.
5. Meyrick TRH, et al. Lichen sclerosus et atrophicus and autoimmunity: a study of 350 women. Br J Dermatol. 1988; 118: 41–46.
6. Cooper SM, et al. The association of lichen sclerosus and erosive lichen planus of the vulva with autoimmune disease: a case-control study. Arch Dermatol. 2008; 144: 1432–1435.
7. Birenbaum DL, Young RC. High prevalence of thyroid disease in patients with lichen sclerosus. J Reprod Med. 2007; 52:28–30.
8. McPherson T, Cooper S. Vulval lichen sclerosus and lichen planus. Dermatol Ther 2010; 23:523.
9. Ashcroft GS, Ashworth JJ. Potential role of estrogens in wound healing. Am J Clin Dermatol. 2003; 4:737–743.
10. Johnson E, et al. Vulvar Skin Atrophy Induced by Topical Glucocorticoids. J Midwifery & Women’s Health. 2012; 57(3): 296-299.
11. Friedrich EG, Kalra PS. Serum levels of sex hormones in vulvar lichen sclerosus, and the effect of topical testosterone. N Engl J Med 1984; 310: 488–91.
12. Ayhan A, et al. Testosterone versus clobetasol for maintenance of vulvar lichen sclerosus associated with variable degrees of squamous cell hyperplasia. Acta Obstet Gynecol Scand. 2007; 86(6): 715-9.
13. Jara EL, et al. Modulating the function of the immune system by thyroid hormones and thyrotropin. Immunol Lett. 2017 Apr; 184: 76-83.
14. Dhabhar FS. Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res. 2014 May; 58(2-3): 193-210.
15. Vitlic A, Lord JM, Phillips AC. Stress, ageing and their influence on functional, cellular and molecular aspects of the immune system. Age (Dordr). 2014 Jun; 36(3): 9631.
16. Morey JN, et al. Current Directions in Stress and Human Immune Function. Current opinion in psychology. 2015; 5: 13-17.
17. Johansson AC, et al. Pain, disability and coping reflected in the diurnal cortisol variability in patients scheduled for lumbar disc surgery. Eur J Pain. 2008 Jul; 12(5): 633-40.
18. Bunker CB. Male genital lichen sclerosus and tacrolimus. Br J Dermatol. 2007 Nov; 157(5): 1079-80.
19. Todd P, et al. Lichen sclerosus and the Köbner phenomenon. Clin Exp Dermatol. 1994 May; 19(3): 262-3.
20. Johansson AC, et al. Eur J Pain. 2008 Jul; 12(5): 633-40
21. Konijeti GG, et al. Efficacy of the Autoimmune Protocol Diet for Inflammatory Bowel Disease. Inflammatory bowel diseases. 2017; 23(11): 2054-2060.
22. Fasano A. Zonulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiological Reviews. 2011; 91: 151-75.
23. Wahls T, Adamson E. The Wahls Protocol: A Radical New Way to Treat All Chronic Autoimmune Conditions Using Paleo Principles. New York, NY: Penguin; 20114.
24. Szodoray P, et al. The complex role of vitamin D in autoimmune diseases. Scand J Immunol. 2008 Sep; 68(3): 261-9.
25. Munger KL, et al.. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006 Dec 20; 296(23): 2832-8.
26. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008 Sep; 20(5): 532-7.
27. Merlino LA, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum. 2004 Jan; 50(1): 72-7.
28. National Institutes of Health. https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/ Accessed April 2, 2018.
29. Handel AE, et al. Vitamin D receptor ChIP-seq in primary CD4+ cells: relationship to serum 25-hydroxyvitamin D levels and autoimmune disease. BMC Med. 2013 Jul 12; 11: 163.
30. Brown N, Panksepp J. Low-dose naltrexone for disease prevention and quality of life. Med Hypotheses. 2009 Mar; 72(3): 333-7.
31. Cree BA, Kornyeyeva E, Goodin DS. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2): 145-50.
32. Smith JP, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: a randomized placebo-controlled trial. Dig Dis Sci. 2011 Jul; 56(7): 2088- 97.
33. Smith JP, et al. Low-dose naltrexone therapy improves active Crohn’s disease. Am J Gastroenterol. 2007 Apr; 102(4): 820-8.
34. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain Clin Rheumatol (2014) 33: 451.
35. Goldstein AT, et al. Intradermal injection of autologous platelet-rich plasma for the treatment of vulvar lichen sclerosus. Journal of the American Academy of Dermatology. 2017; 76(1): 158-60.
36. Behnia-Willison F, et al. Use of Platelet-rich Plasma for Vulvovaginal Autoimmune Conditions Like Lichen Sclerosus. Plastic and Reconstructive Surgery Global Open. 2016;4(11):e1124.